Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
Not too late to donate: Give money, give blood, donate goods, volunteer. Here's your guide to help our western NC neighbors
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
26.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
September 27, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
2 Growth Stocks to Buy With Less Than $100
September 26, 2024
No need to break the bank to get in on these likely long-term winners.
Via
The Motley Fool
A Closer Look at 5 Analyst Recommendations For Exelixis
September 18, 2024
Via
Benzinga
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
September 06, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
NASDAQ:EXEL, an undervalued stock with good fundamentals.
August 15, 2024
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
August 08, 2024
Via
Benzinga
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
May 01, 2024
Via
Benzinga
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
August 07, 2024
Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance....
Via
Benzinga
Exposures
Product Safety
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
August 07, 2024
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
August 07, 2024
EXEL earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via
Chartmill
What Analysts Are Saying About Exelixis Stock
April 10, 2024
Via
Benzinga
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
EXEL stock results show that Exelixis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
August 06, 2024
U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
July 18, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
August 06, 2024
Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
June 27, 2024
When you look at EXELIXIS INC (NASDAQ:EXEL), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
June 06, 2024
EXELIXIS INC (NASDAQ:EXEL) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
May 31, 2024
Via
Benzinga
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
May 15, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
May 12, 2024
These stocks are both experts in their respective fields.
Via
The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
May 10, 2024
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Via
Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
May 08, 2024
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.
Via
InvestorPlace
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
May 01, 2024
EXEL earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
April 30, 2024
EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
The Top 3 Biotech Stocks to Buy in April 2024
April 27, 2024
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.
Via
InvestorPlace
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.